Primary care market access intelligence · England

A complete picture of any drug across NHS primary care.

Vima Access pulls formulary status, prescribing trends, clinical system listings, wholesaler audits, and reimbursement into one place. Then it gives your team the tools to track launches, suggest formulary changes, raise tickets, and watch the drugs that matter, daily.

42
ICBs covered
ready for the post-April-2026 mergers
6
Data panels per drug
from dm+d to wholesaler
4
Built-in workflows
watch, propose, launch, support
1
Place to act
brand or generic, any ICB
02 · The gap

The tools your team already has, and what they miss.

Most market access teams piece together data from three or four sources, plus a spreadsheet or two. None of those tools gives a single place to act. Vima Access starts where they stop, then adds the operational layer none of them have.

IQVIA
Industry incumbent
What it does
Strong on national volume and competitor benchmarks across the full pharma stack.
What it misses
Thin on per-ICB formulary, dispensing system listings, and wholesaler catalogue.
Datapharm / eMC
Regulatory reference
What it does
Authoritative for SmPC and product information for licensed products.
What it misses
No prescribing data, no formulary tracking, no operational workflows.
OpenPrescribing
Free public tool
What it does
Excellent for trends on the public NHSBSA cut at national, ICB, and practice level.
What it misses
No formulary, no clinical systems, no wholesaler, no launch tracking.
Vima Access
That’s us
Data plus the workflows to act
What it does
Six data panels per drug, plus four built-in workflows: Watched drugs, Formulary proposals, Launch Tracker, Support tickets.
What it misses
That is the point: a single place where decisions get made and recorded.
03 · The data layer

Six panels per drug. Sourced, dated, verified.

Every panel cites its source and shows when it was last verified, by whom. Quarterly review cycle on curated data, weekly refresh on dm+d and prescribing.

01
Product information
dm+d-linked names, identifiers, strengths, packs, pricing, and classification.
Source · TRUD · weekly
02
Prescribing trends
National and ICB-level monthly items, with brand-aware aggregation across strengths.
Source · NHSBSA EPD · monthly
03
ICB formulary status
RAG classification per ICB, with prescriber-level, restrictions, and source URL.
Source · Curated · quarterly
04
Clinical system listings
Listing state across EMIS, SystmOne, Vision, and ProScript Connect.
Source · Curated · continuous
05
Wholesaler listing audit
Catalogue name, PIP code, listed price across AAH, Alliance, Phoenix.
Source · Curated · quarterly
06
Reimbursement
Drug Tariff category, list price, ACBS approval, monthly price concessions.
Source · NHSBSA Drug Tariff
04 · The workflow layer

Workflows that turn data into action.

Four built-in tools that sit on top of the panels so your team does the work in one place, not five.

01
Included
Watched drugs and alerts
  • Watch any drug in your portfolio with one click.
  • Email when something changes: formulary status moves, listing appears, wholesaler stops stocking, dm+d entry amended.
  • Choose immediate, 08:00 UK daily digest, weekly Monday digest, or in-platform only.
02
Included
Formulary proposals
  • Spot an out-of-date Panel 3 row, hit 'Suggest a change', propose the edit with a citable source.
  • Vima reviews. Approved proposals write to the live entry in a single atomic transaction.
  • One active proposal per drug-ICB pair so suggestions never conflict.
03
Per-launch add-on
Launch Tracker
  • End-to-end view of a launch, anchored on the dm+d effective date.
  • Six milestone categories: regulatory, commercial readiness, NHSBSA submission, wholesaler, clinical systems, post-launch.
  • Auto-detection from panel data, slip-risk warnings, daily email digest at 08:00 UK.
04
Included
Support tickets
  • Threaded conversation with Vima Clinical for everything not covered by a structured workflow.
  • Categorise by topic, optionally attach a drug, attach files up to 5 MB.
  • Four-state flow (Open, In progress, Awaiting client, Resolved) with email at every transition.
05 · Launch Tracker

Stop running launches in a spreadsheet.

Purpose-built for UK pharma launches, end to end. Vima’s Launch Tracker takes a drug from MHRA approval through wholesaler stocking, EMIS and SystmOne listings, and the first six months of prescribing growth, in one view. It detects what it can from the panels and surfaces slip-risk warnings when the dm+d effective date drifts past the cadence expected for each downstream system.

Auto-detection from panel data
Manual entry only where the data is not on the platform: regulatory, commercial readiness, NHSBSA submission.
Slip-risk warnings rooted in real lag patterns
NHSBSA 10-working-day submission window. EMIS 4-to-6 week lag. FDB Drug-Tariff dependency.
Outreach loops tracked with cutoffs
Optum (EMIS) and FDB (SystmOne) monthly MKB and bulletin cutoff dates logged per launch.
Daily email digest at 08:00 UK
Every watched launch, every morning. Auto-detected milestones, open risks, and what changed in the last 24 hours.
Vimaxa 100/6/10 mcg
NEW PRODUCT LAUNCH · Q3 2026
On track
MHRA approval confirmed
14 Mar 2026
dm+d notification submitted
2 Apr 2026
dm+d effective date confirmed
17 Apr 2026 (Thu)
Catalogue listed at AAH, Alliance
Phoenix pending
EMIS Web listing live
Expected 8 May
SystmOne listing live
Expected 15 May
First prescribing data visible
~Aug 2026
Open slip risks1 · Phoenix not yet stocking
Flagged when a wholesaler is still pending 14 days past the dm+d effective date.

Vimaxa is a fictional combination inhaler shown for illustration. All other figures (ICB names, wholesalers, dates) are consistent with how the platform operates with real product data.

06 · Behind the platform

“After years working on NHS primary care market access, the same gap kept showing up. The data layer is necessary, but it is not sufficient. Vima Access is built to be both layers in one.”

Vima Clinical LtdFounded by pharmacists with NHS market access experience.
42
ICBs covered, ready for the post-April-2026 mergers as they land.
6
data panels per drug, every panel sourced and dated.
4
built-in workflows: Watched, Proposals, Launch Tracker, Support.
Quarterly
verification cycle on curated rows, with a named verifier.
07 · Pricing

Annual subscription. Per SKU. Pricing on request.

Designed to scale with your portfolio, with volume bands that get more efficient as the SKU count grows. Launch Tracker is an optional add-on for SKUs in active launch.

Per-SKU subscription

Annual fee per SKU on a four-band volume scale. Cost per SKU gets more efficient as your portfolio grows. Minimum annual fee. Two-year default contract, annual billing up front.

  • ·All 6 data panels
  • ·All 42 ICBs
  • ·Watched, Proposals, Support included
Onboarding (per SKU)

One-time fee per SKU joining the platform. Covers dm+d mapping, baseline formulary research, listing verification, wholesaler audit, reimbursement classification.

  • ·Charged once per SKU
  • ·Same fee for initial cohort or mid-contract adds
  • ·Demo-only onboarding flow
Launch Tracker add-on

Optional, priced per launch event. Charged when a new SKU is onboarded or a pack change is initiated. Includes the full launch lifecycle: MHRA approval through six months post first prescription.

  • ·One-time per launch event
  • ·Auto-detection + slip-risk warnings
  • ·Daily email digest at 08:00 UK

See your portfolio in Vima Access.

Tell us which products you’d want to see and we’ll prepare a tailored demo with real data, typically within five working days.

No marketing spam. We’ll respond within two working days.